In our recent report, we verified the strong synergistic tumor inhibition of pyrotinib (a novel small-molecule tyrosine kinase inhibitor mainly targeting HER2) combined with CDK4/6 inhibitor in HER2-positive GC patients [26]. Here, CDK4 is linked to gastric cancer.